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Acute otitis media (AOM) is a very common con- 
dition, but its management remains difficult. Accurate 
recognition of the disease represents the first dilemma. 
None of the symptoms are specific. Even the red 
tympanic membrane can be caused by the child’s crying 
or the viral upper respiratory infection that usually 
accompanies the disease. So AOM is commonly over- 
diagnosed. Since the first line antibiotic therapy is 
considered as safe and well tolerated, an antibiotic is 
often prescribed, even when the diagnosis is uncertain, 
for the satisfaction of both the parents and the 
physician. 
A famous Dutch study [l] reported no difference 
in outcome after antibiotics, myringotomy, antibiotics 
combined with myringotomy, or placebo. Hence an 
approach consists to restrict antimicrobial therapy to 
children continuing to have symptoms after a period of 
24-72 hours of observation. A spontaneous resolution 
of acute symptoms occurs in the majority of the cases, 
but the calculations done here by Grenier [2] suggest 
that this “masterful inactivity” may cost more than 
an antibiotic therapy initiated as soon as the diagnosis 
is suspected because of a greater expense for medical 
visits. 
Once the decision to start antibiotic treatment has 
been taken, the choice of the antibiotic therapy comes 
next, and it is clear that it should be addressed against 
the main pathogens involved. The bacterial aetiology 
of AOM is well-known: three organisms represent 
up to 80-90% of all causes, Streptococcus pneumoniae, 
Haemophilus influenzae and to a lesser degree, Moraxella 
catarrhalis [3]. In most cases, microbiology testing 
is not available, but a few clinical clues exist which 
can somewhat orientate the clinician toward a given 
pathogen. So the rare otitis conjunctivitis syndrome is 
indicative of an H. injuenzae aetiology in 75% of the 
cases [4] and a temperature above 38,5” is associated 
to the pneumococcal aetiology in SO% of the cases [S]. 
Some risk factors of nasopharyngeal carriage with 
penicillin-resistant S. pneumoniae have been identified: 
age less than eighteen months, attendance in day care 
centers, home in urbanized areas, antibiotic therapy in 
the three last months, and previous failures of otitis 
media [6]. 
Keeping in mind the spontaneous clearance of 
the different offending agents (80%, 56% and 20%, 
respectively for S. pneumoniae, H .  influenzae and M.  
catarrhalis [7]) and the different morbidity and rates of 
potential complications, it is clearly of paramount 
importance to offer adequate coverage for the possible 
pneumococcal aetiology. The prevalence of local anti- 
biotic resistance is, from this point of view, crucial if a 
rational choice of the empiric treatment is to be made. 
In this regard, it is important to know the current 
prevalence of penicillin-resistant pneumococci and of 
p-lactamase producing H .  inzuenzae. Penicillin-resist- 
ance in pneumococci affects to a different degree all 
p-lactams. It is not due to P-lactamase production and 
can be overcome by increasing the concentration of the 
antibiotic at the site of infection. It is also important to 
consider the frequency of resistance to other agents. 
Penicillin-resistant pneumococci are often resistant to 
macrolides and cotrimoxazole; in non-typable Haemo- 
philus influenzae, resistance to cotrimoxazole has been 
reported, in many areas of the world [8].  From these 
considerations it appears that the use of p-lactams active 
in vivo against these resistant organisms will be effective 
with dosages that will produce concentrations above 
the MIC of the offending strain in the case of 
S. pneumoniae and could resist the (3-lactamase hydro- 
lysis in the case of H .  injuenzae. The absence of 
comparative clinical trials with well defined end-points 
including bacterial eradication from the middle ear 
for the currently used antimicrobials, forces us to 
rely, when choosing between the different therapeutic 
options, on microbiological and pharmacological 
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criteria. Of  particular importance in this regard, are 
the results obtained in the experimental model of 
AOM and the very few studies available in humans of 
eradication rates using different antimicrobial agents. 
Thus, in the gerbil model with AOM caused by a 
penicillin-resistant pneumococcus, Barry et al. [9] have 
shown that increased doses of amoxicillin were able 
to clear the middle ear infection. Middle ear concen- 
trations were above the corresponding MICs for only 
part of the time between doses but always for more that 
2.5 hours. In humans, Dagan et al. [lo], have shown 
that only those p-lactams active in vitro against 
pneumococci and non-typable H. injuenzae will 
provide reasonable bacteriologic results in vivo; among 
the currently available oral p-lactams agents amoxicillin 
represents the best choice in areas with a high 
prevalence of penicillin-resistant pneumococci and 
resistance to cotrimoxazole. Thus, it appears that the 
relation between MIC, serum concentration and 
middle ear concentration are the main parameters to 
use in the choice of the p-lactam agent and its dosage. 
If amoxicillin is used, and following the antibiotic 
regimens proposed by G.H. McCracken [I 11, dosages 
of 60-80mg/Kg/day are recommended in areas of 
high prevalence of penicillin-resistant pneumococci. A 
second option would be to use the combination of 
amoxicillin/clavulanic acid, ideally with a 7:l ratio that 
would permit to dose amoxicillin 60-80 mg/Kg/day 
without increasing the dose of clavulanic acid; in doing 
so, the combination would increase the percentage of 
theoric therapeutic success to 90-92%. 
Oral cephalosporins such as cefuroxime axetil or 
cefodoxime proxetil would be a valid alternative for 
the treatment of AOM. Newer macrolides especially 
clarithromycin and azithromycin which exhibit im- 
proved activity against H. injuenzae represent another 
therapeutic option in areas with low prevalence of 
macrolide-resistance in the pneumococci. 
The absence of improvement with antibiotic treat- 
ment could be due to a viral infection or coinfection 
with a virus. Occasionally, the lack of response is due 
to an incorrect antibiotic choice or to the presence 
of a bacterial agent resistant to it. Only when the 
clinical symptoms persist and are severe, should the 
possibility of infection due to a S. pneumoniae with high 
level resistance to penicillin be considered. A thera- 
peutic option here would be cefiriaxone (50 mg/IM/ 
day) for 3-5 days. 
The optimal duration of administration is another 
area of uncertainty. Seven to ten days of antibiotic 
treatment is often considered as adequate, but five- 
day prescriptions, commonly used in UK, have been 
reported to be as effective as 7-10 day courses [2 ] ,  and 
the 3-day course is advocated for azithromycin. 
Despite all our efforts, and even when a correctly 
dosed and appropriate drug is taken by a compliant 
patient, the present antibiotic therapy is not fully 
satisfactory: about 10% of children experiencing AOM 
are unresponsive to treatment [12], and recurrent acute 
otitis media still represents a major source of consul- 
tation to otolaryngologists [13]. 
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